Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.

Frontiers in immunology - 1 Jan 2020

Passarelli Anna, Aieta Michele, Sgambato Alessandro, Gridelli Cesare

Abstract excerpt

Despite the relevant antitumor efficacy of immunotherapy in advanced non-small cell lung cancer (NSCLC), the results in patients whose cancer harbors activating epidermal growth factor receptor (EGFR) mutations are disappointing. The biological mechanisms underlying immune escape and both unresponsiveness and resistance to immunotherapy in EGFR-mutant NSCLC patients have been partially investigated. To this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-1

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Tumor Escape

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32760402
DOI: 10.3389/fimmu.2020.01479
PMCID: PMC7371983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.PMID 32760402Read ↗

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.Semantic proximity Read ↗

The Inhibitory Effect of Adenosine on Tumor Adaptive Immunity and Intervention StrategiesSemantic proximity Read ↗

The regulation of CD73 in non-small cell lung cancer.Semantic proximity Read ↗

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39Semantic proximity Read ↗

Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot StudySemantic proximity Read ↗

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.Semantic proximity Read ↗

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferationSemantic proximity Read ↗

GFPT2 controls immune evasion in EGFR-mutated non-small cell lung cancerSemantic proximity Read ↗

Fatty acids in the tumor microenvironment reprogram neutrophils to induce immunosuppression via adenosineSemantic proximity Read ↗

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.